Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | GLP1R | P43220 | 4/20 | 0.34 |
| ▸ | VDR | P11473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1483027 | 0.90 | PDE10A (0.39) | HTR2AHTR2CSLC6A4NR1H4PDE10A | |
| SCHEMBL1482854 | 0.83 | NR1H4 (0.42) | HTR2AHTR2CSLC6A4NR1H4CYP11B1 | |
| SCHEMBL1482050 | 0.83 | NR1H4 (0.44) | HTR2AHTR2CSLC6A4NR1H4PDE10A | |
| SCHEMBL1482732 | 0.83 | CNR2 (0.42) | NR1H4CYP11B1CYP11B2CNR2NPSR1 | |
| SCHEMBL1482276 | 0.82 | NR1H4 (0.43) | HTR2AHTR2CSLC6A4NR1H4PDE10A | |
| SCHEMBL1482102 | 0.81 | NR1H4 (0.42) | HTR2AHTR2CSLC6A4NR1H4CYP11B2 | |
| SCHEMBL1482478 | 0.79 | CNR2 (0.40) | NR1H4CYP11B1CYP11B2CNR2NPSR1 | |
| SCHEMBL1482189 | 0.79 | NR1H4 (0.42) | HTR2AHTR2CSLC6A4NR1H4CNR2 | |
| SCHEMBL1482669 | 0.78 | NR1H4 (0.41) | HTR2AHTR2CSLC6A4NR1H4CYP11B1 | |
| SCHEMBL1482995 | 0.78 | KCNN4 (0.37) | CYP11B1CYP11B2NPSR1PDE10AGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2483247-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011039130-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-07 | — | — | WO | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | HTR2A 2136/4885HTR2C 1402/4885SLC6A4 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.